The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients

Table 1 Percent completing M6 and probability of retention at M3 and M6 by patient baseline characteristics and primary condition in 1011 participants

Patient baseline characteristics	Completed M6 (%)	Kaplan–Meier estimator
		Probability of remaining in study
		M3	M6	p
Gender				0.382
Male	175/432 (40.5)	0.70	0.41
Female	244/578 (42.2)	0.74	0.42
Education				0.299
High school or lower	178/451 (39.5)	0.71	0.39
College or higher	241/560 (43.0)	0.73	0.43
Marital status				0.272
Single/divorced/widowed/separated	175/450 (38.9)	0.72	0.39
Married/living as married	244/561 (43.5)	0.72	0.43
Age				0.279
< 25	5/18 (27.8)	0.78	0.28
25–39	102/264 (38.6)	0.69	0.39
40–55	141/345 (40.9)	0.70	0.41
> 55	171/384 (44.5)	0.75	0.45
Age				0.107
< 55	238/602 (39.5)	0.70	0.40
≥ 55	181/409 (44.3)	0.74	0.44
Used cannabis 5 or more times in the last 12 months				0.459
No	245/580 (42.2)	0.73	0.42
Yes	168/415 (40.5)	0.70	0.40
Primary medical condition you currently treat with medical cannabis				0.913
Anxiety disorder	37/98 (37.8)	0.73	0.38
Arthritis	27/63 (42.9)	0.75	0.43
Cancer/leukemia	8/15 (53.3)	0.73	0.53
Chronic pain	298/703 (42.4)	0.72	0.42
Crohn’s disease	1/6 (16.7)	0.67	0.17
Epilepsy	3/5 (60.0)	0.80	0.60
Gastrointestinal disorder	3/6 (50.0)	0.83	0.50
Headache	8/23 (34.8)	0.78	0.35
Insomnia	20/48 (41.7)	0.65	0.42
Movement disorder	2/8 (25.0)	0.63	0.25
PTSD	2/8 (25.0)	0.63	0.25
Other	8/18 (44.4)	0.78	0.44
Primary medical condition you currently treat with medical cannabis				0.862
Pain	333/789 (42.2)	0.72	0.42
Mental health issues	40/109 (36.7)	0.73	0.37
Insomnia	20/48 (41.7)	0.65	0.42
Other	26/64 (40.6)	0.77	0.41

ISSN: 2522-5782